A5049778223- Autoimmune Neurological Disorders and Treatments
- Long-Term Effects of COVID-19
- Infectious Encephalopathies and Encephalitis
- Multiple Sclerosis Research Studies
- Systemic Sclerosis and Related Diseases
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Systemic Lupus Erythematosus Research
- Epilepsy research and treatment
- Peripheral Neuropathies and Disorders
- Neurological and metabolic disorders
- Vestibular and auditory disorders
- Mitochondrial Function and Pathology
- Pharmacological Effects and Toxicity Studies
- Neonatal and fetal brain pathology
- Autoimmune Bullous Skin Diseases
- Neuroscience and Neuropharmacology Research
- Glycogen Storage Diseases and Myoclonus
- Neuroscience of respiration and sleep
- Polyomavirus and related diseases
- Antiplatelet Therapy and Cardiovascular Diseases
- Cerebrovascular and genetic disorders
- Intracerebral and Subarachnoid Hemorrhage Research
- Neurological Complications and Syndromes
- Thermal Regulation in Medicine
Hospital Santa Caterina
2021-2025
Fondation Ophtalmologique Adolphe de Rothschild
2025
Vall d'Hebron Institut de Recerca
2024
Hospital Clínic de Barcelona
2024
Universitat Autònoma de Barcelona
2024
Institut d'Investigació Biomèdica de Girona
2021-2023
Hospital Universitari de Girona Doctor Josep Trueta
2020-2023
University of Girona
2023
Clínica Girona
2023
Hospital Universitario de Guadalajara
2017-2019
Neurological symptoms are common manifestation in acute COVID-19. This includes hyper- and hypokinetic movement disorders. Data on their outcome, however, is limited.Cases with new-onset COVID-19-associated disorders were identified by searching the literature. Authors contacted for outcome data which reviewed analyzed.Movement began 12.6 days average after initial onset of 92% patients required hospital admission (mean duration 23 days). In a fraction (6 27; 22%; 4 males/2 females, mean age...
To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up assess their utility for predicting relapses disability. This retrospective multicentric cohort study included patients aged 16 years older meeting MOGAD 2023 criteria, with samples collected baseline (≤3 months from onset) (≥6 baseline), age-matched time to sampling-matched multiple sclerosis (MS). Eleven cytokines were assessed using ELLA...
Background The assessment of clinical prognosis in autoimmune encephalitis: Girona (ACPE-Gi) score is a scale for evaluating the severity acute phase encephalitis (AE) and predicting risk disability at 3 months, measured by modified Rankin (mRS). Methods Patients were strictly diagnosed with AE according to current criteria between 1 January 2009 31 March 2023 University Hospital Dr. Josep Trueta Girona, Catalonia, Spain. ACPE-Gi included 14 items, every item was scored from 0 3, depending...
Background Serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) have emerged as important biomarkers in multiple sclerosis (MS) aquaporin-4 seropositive neuromyelitis optica spectrum disorder (AQP4-NMOSD). However, their interest myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) remains unclear. Our aim was to characterise sNfL sGFAP profile analyse usefulness predicting relapses disability MOGAD. Methods Retrospective study of adult...
4 patients suffering severe neuromuscular diseases were subjected to a subtentorial implantation of electrodes over the anterior cerebellar lobe surface. Chronic stimulation was applied for 90 min 7 h daily, with rate 20–180 Hz, 6–10 V and schedule 15 ‘on’, ‘off’. Some improvement observed in 3 treated high frequency stimulation. 1 patient suffered seizures after months chronic In 2 cases, posterior fossa explorations necessary revision apparatus marked meningeal proliferation surrounding...
An association has been found between the presence of lipid-specific oligoclonal IgM bands (LS-OCMB) in cerebrospinal fluid and a more severe clinical multiple sclerosis course.To investigate as prognostic biomarker cognitive impairment early stages sclerosis.Forty-four patients underwent neuropsychological assessment at baseline 4 years. Cognitive performance follow-up was compared adjusting by age, education, anxiety-depression, performance.LS-OCMB+ only performed worse for Long-Term...
The role of the complement system in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is not completely understood, and studies exploring its potential utility for diagnosis prognosis are lacking. We aimed to investigate value factors (CFs) as diagnostic prognostic biomarkers patients with MOGAD.
View Supplementary Video 1